To investigate these hypotheses, we conducted a comprehensive characterization of EVs released by melanoma A375 cells following sublethal Dox treatment, using nanoparticle tracking analysis, electron microscopy, and immunoblotting for canonical EV markers (CD9, CD63, CD81, Tumor susceptibility gene 101 protein TSG101). This evidence concerns the gene TSG101 and melanoma.